search buttonmobile navigation expand button

Need Assistance?

Back to Search Results


STRENGTH - A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

The main purpose of the study is to check whether taking Epanova® along with a statin therapy lowers the risk of what are known as ‘Major Adverse Cardiovascular Events’ (MACE). It will be compared to taking statin with a placebo (corn oil). The study will be done in people with persistently high levels of triglycerides in their blood. A cardiovascular event is an event that involves the heart or the brain which are both fed by blood vessels. So, included in the definition of MACE are heart attack and stroke, as well as any death from one of those events.

Trial Information
Principal Investigator: Dr. Daniel Lee

Contact: Study Coordinator
Phone (Main): 989-891-8189

IRB Number: 2016-00011 02104817

More Information: